Syndecan-1 Expression Is Increased in the Aortic Wall of Patients with Type 2 Diabetes but Is Unrelated to Elevated Fasting Plasma Glucagon-Like Peptide-1
Open Access
- 20 June 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (6), 697
- https://doi.org/10.3390/biomedicines9060697
Abstract
A reduced prevalence of a thoracic aortic aneurysm (thoracic AA) is observed in type 2 diabetes (T2D). Glucagon-like peptide-1 (GLP-1)/GLP-1-based anti-diabetic therapy has indicated protective effects in thoracic AA and regulates the processes controlling the vascular tissue expression of Syndecan-1 (Sdc-1). Sdc-1 expression on macrophages infiltrating the aortic tissue contributes to a counter-regulatory response to thoracic AA formation in animal models through the interplay with inflammation/proteolytic activity. We hypothesized that elevated fasting plasma GLP-1 (fpGLP-1) increases the aortic Sdc-1 expression in T2D, which may contribute to a reduced prevalence of thoracic AA. Consequently, we determined whether T2D/thoracic AA associates with an altered Sdc-1 expression in the aortic tissue and the possible associations with fpGLP-1 and inflammation/proteolytic activity. From a cohort of surgical patients with an aortic valve pathology, we compared different disease groups (T2D/thoracic AA) with the same sub-cohort group of controls (patients without T2D and thoracic AA). The MMP-2 activity and Sdc-1, GLP-1R and CD68 expression were analyzed in the aortic tissue. GLP-1, Sdc-1 and cytokines were analyzed in the plasma. The aortic Sdc-1 expression was increased in T2D patients but did not correlate with fpGLP-1. Thoracic AA was associated with an increased aortic expression of Sdc-1 and the macrophage marker CD68. CD68 was not detected in T2D. In conclusion, an increased aortic Sdc-1 expression may contribute to a reduced prevalence of thoracic AA in T2D.Funding Information
- Mats Klebergs Stiftelse (NA)
- Sven och Dagmar Saléns Stifelser (NA, NA, NA)
This publication has 57 references indexed in Scilit:
- Diabetes and Reduced Risk for Thoracic Aortic Aneurysms and Dissections: A Nationwide Case‐Control StudyJournal of the American Heart Association, 2012
- Matrix Metalloproteinase Inhibitors as Investigative Tools in the Pathogenesis and Management of Vascular DiseaseExperientia Supplementum, 2012
- Syndecan-1 Displays a Protective Role in Aortic Aneurysm Formation by Modulating T Cell–Mediated ResponsesArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Molecular functions of syndecan-1 in diseaseMatrix Biology, 2012
- Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearanceJournal of Hepatology, 2011
- Lessons on the pathogenesis of aneurysm from heritable conditionsNature, 2011
- 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic DiseaseJournal of the American College of Cardiology, 2010
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4Diabetes, 2010
- Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on enterocyte shedding of syndecan-1 and associated decreases in internalization of Listeria monocytogenes and Staphylococcus aureusCytokine, 2006
- Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissectionsThe Journal of Thoracic and Cardiovascular Surgery, 2006